ANTHRANOL 1.0

Main information

  • Trade name:
  • ANTHRANOL 1.0
  • Dosage:
  • 1.0 %w/w
  • Pharmaceutical form:
  • Ointment
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ANTHRANOL 1.0
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0144/017/001
  • Authorization date:
  • 23-03-1990
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

PartII

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

Anthranol1.0%

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Dithranol1.0%w/w.

Forexcipients,seesection6.1.

3PHARMACEUTICALFORM

Ointment

Awaxyyellowointment.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Anthranol1.0Ointmentisindicatedforthetopicaltreatmentofpsoriasis.

4.2Posologyandmethodofadministration

Anthranol1.0Ointmentisoneofarangeofdithranolproducts,whichinclude0.4and2.0ointments.

TreatmentshouldbeginwithAnthranol0.4.Clinicalresponseandtolerancewilldeterminethenecessityfor

progressiontoAnthranol1.0andsubsequentlyAnthranol2.0.

Applytheointmentoncedaily,sparinglytothepsoriaticplaque.Surroundingnormalskinshouldbeprotectedwith

whitesoftparaffin.Leavetheointmentonfortherequiredtimethenremoveexcessointmentwithapapertissueand

washofftheremainderthoroughly.

IfAnthranolhasbeenappliedtothescalp,theointmentshouldberemovedbyshampooing.

Theinitialdailytreatmenttimewitheachstrengthshouldnotexceed10minutes.Thetimemaybeincreasedgradually

overaperiodof7daystoamaximumof30minutes.Thedailytreatmenttimeshouldnotnormallyexceed30minutes.

Intheeventofundueirritation,stoptreatmentfor2daysandresumeonalternatedays.

Treatmentshouldbecontinuedattheoptimumtoleratedstrengthandleave-ontime,dependingonpatientresponse.

4.3Contraindications

Anthranol1.0Ointmentiscontra-indicatedinpustularpsoriasisandisnotsuitableforthetreatmentofacutepsoriasis.

Itshouldnotbeusedbypatientswithknownhypersensitivitytotheingredients.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 06/12/2006 CRN 2030816 page number: 1

4.4Specialwarningsandprecautionsforuse

Dithranolisastrongirritant,thehandsshouldalwaysbewashedafteruseandtheproductkeptawayfromtheeyes.

Shouldcontactwiththeeyesoccur,batheimmediatelywithwaterandseekmedicaladvice.

Theproductwillcausestaininganddiscolourationoftheskin.Itwillalsostainordiscolourclothingandmaystain

bathroomware.Stainsonclothingshouldbeassumedtobepermanent;stainsonbathroomwaremayberemovedby

bleach.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

None.

4.6Pregnancyandlactation

AlthoughthereisnoevidencetosupportthesafetyofAnthranolinpregnancyandlactation,noadverseeffectshave

beenreported.

4.7Effectsonabilitytodriveandusemachines

None.

4.8Undesirableeffects

Dithranolpreparationscancauseirritation;ifthisdevelops,orrednessisobservedonadjacentnormalskin,the

frequencyofapplicationshouldbereduced.

4.9Overdose

Notapplicable.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Theuseofdithranolinthetreatmentofpsoriasisiswellestablished.Ithasbeensuggestedthatthemodeofaction

involvescombinationwithdeoxyribonucleicacidandothernucleicacids,inhibitingthesynthesisofnucleicprotein

andthusdecreasingthecellularproliferation,whichisincreasedinthepsoriaticepidermis.

5.2Pharmacokineticproperties

Theproductisatopicalpreparation,whichactslocallyatthesiteofapplication.Pharmacokineticdataarenot

applicable.

5.3Preclinicalsafetydata

Notapplicable.Dithranolhasbeeninwide-spreaduseformanyyears.Therelevantinformationisgiveninsection4of

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 06/12/2006 CRN 2030816 page number: 2

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Whitesoftparaffin

Cetylalcohol

Sodiumlaurilsulfate

Salicylicacid

Lightliquidparaffin

6.2Incompatibilities

Notapplicable.

6.3ShelfLife

3years.

6.4Specialprecautionsforstorage

Donotstoreabove25 o

6.5Natureandcontentsofcontainer

Internallylacqueredaluminiumtubesof50g.

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Nospecialrequirements.

7MARKETINGAUTHORISATIONHOLDER

StiefelLaboratories(UK)Ltd.

HoltspurLane

WooburnGreen

HighWycombe

Buckinghamshire

HP100AU

England

8MARKETINGAUTHORISATIONNUMBER

PA144/17/1

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:23March1990

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 06/12/2006 CRN 2030816 page number: 3

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 06/12/2006 CRN 2030816 page number: 4